Novartis Ag ADR
(NVS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 8,071,000 | 7,147,000 | 12,800,000 | 7,703,000 | 6,698,000 |
| Depreciation Amortization | 6,129,000 | 5,788,000 | 5,217,000 | 6,332,000 | 6,175,000 |
| Income taxes - deferred | 1,807,000 | 1,793,000 | 1,295,000 | 1,296,000 | 1,119,000 |
| Accounts receivable | 137,000 | -980,000 | -544,000 | -204,000 | -229,000 |
| Accounts payable and accrued liabilities | -324,000 | 553,000 | 252,000 | 58,000 | -587,000 |
| Other Working Capital | -291,000 | 199,000 | 576,000 | 244,000 | -2,188,000 |
| Other Operating Activity | -1,879,000 | -875,000 | -5,324,000 | -2,808,000 | 487,000 |
| Operating Cash Flow | $13,650,000 | $13,625,000 | $14,272,000 | $12,621,000 | $11,475,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,408,000 | 2,333,000 | -1,968,000 | -31,000 | 92,000 |
| PPE Investments | -1,187,000 | -522,000 | -1,152,000 | -1,604,000 | -1,701,000 |
| Net Acquisitions | -10,091,000 | -4,925,000 | -14,684,000 | -895,000 | -1,513,000 |
| Purchase Of Investment | -230,000 | -302,000 | 12,649,000 | -468,000 | -247,000 |
| Sale Of Investment | 723,000 | 1,152,000 | 165,000 | 330,000 | 247,000 |
| Purchase Sale Intangibles | -930,000 | 95,000 | -571,000 | -410,000 | -170,000 |
| Other Investing Activity | -989,000 | 38,000 | -601,000 | -451,000 | -319,000 |
| Investing Cash Flow | $-13,182,000 | $-2,226,000 | $-5,591,000 | $-3,119,000 | $-3,441,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,261,000 | -1,582,000 | 1,687,000 | -755,000 | 1,816,000 |
| Debt Issued | 7,126,000 | 93,000 | 2,856,000 | 4,933,000 | 1,935,000 |
| Debt Repayment | -2,003,000 | -3,195,000 | -366,000 | -188,000 | -1,696,000 |
| Common Stock Issued | N/A | 201,000 | N/A | 252,000 | N/A |
| Common Stock Repurchased | -2,842,000 | -5,533,000 | -2,036,000 | -5,490,000 | -1,109,000 |
| Dividend Paid | -6,987,000 | -6,645,000 | -6,966,000 | -6,485,000 | -6,468,000 |
| Other Financing Activity | 237,000 | 3,034,000 | 581,000 | 0 | 208,000 |
| Financing Cash Flow | $-2,208,000 | $-13,627,000 | $-4,244,000 | $-7,733,000 | $-5,314,000 |
| Exchange Rate Effect | 286,000 | 69,000 | -26,000 | 84,000 | -387,000 |
| Beginning Cash Position | 11,112,000 | 13,271,000 | 8,860,000 | 7,007,000 | 4,674,000 |
| End Cash Position | 9,658,000 | 11,112,000 | 13,271,000 | 8,860,000 | 7,007,000 |
| Net Cash Flow | $-1,454,000 | $-2,159,000 | $4,411,000 | $1,853,000 | $2,333,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 13,650,000 | 13,625,000 | 14,272,000 | 12,621,000 | 11,475,000 |
| Capital Expenditure | -1,275,000 | -1,379,000 | -1,254,000 | -1,696,000 | -1,862,000 |
| Free Cash Flow | 12,375,000 | 12,246,000 | 13,018,000 | 10,925,000 | 9,613,000 |